Cite
Abstract P4-15-01: Integrin avb6 is a therapeutic target for high-risk breast cancer and enhances trastuzumab efficacy
MLA
Jane Warwick, et al. “Abstract P4-15-01: Integrin Avb6 Is a Therapeutic Target for High-Risk Breast Cancer and Enhances Trastuzumab Efficacy.” Cancer Research, vol. 73, Dec. 2013, pp. P4-15. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........44732d5e8a4caea6971d2f4c90a1551e&authtype=sso&custid=ns315887.
APA
Jane Warwick, P Quinlan, William J. Tapper, Diana Eccles, Lee B. Jordan, P Chou, C Gillet, Antonio Saha, Shelia M. Violette, Jane Kendrew, AM Thompson, Stephen W. Duffy, R L Bowen, Andrew R. Green, Simon T. Barry, A Brentall, Rhian Gabe, Ian O. Ellis, Kate Moore, … Paul H. Weinreb. (2013). Abstract P4-15-01: Integrin avb6 is a therapeutic target for high-risk breast cancer and enhances trastuzumab efficacy. Cancer Research, 73, P4-15.
Chicago
Jane Warwick, P Quinlan, William J. Tapper, Diana Eccles, Lee B. Jordan, P Chou, C Gillet, et al. 2013. “Abstract P4-15-01: Integrin Avb6 Is a Therapeutic Target for High-Risk Breast Cancer and Enhances Trastuzumab Efficacy.” Cancer Research 73 (December): P4-15. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........44732d5e8a4caea6971d2f4c90a1551e&authtype=sso&custid=ns315887.